Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer ; volume:11 ; number:12 ; year:2019 ; extent:17
EMBO molecular medicine / European Molecular Biology Organization ; 11, Heft 12 (2019) (gesamt 17)
- Creator
-
Yun, Mi Ran
Choi, Hun Mi
Lee, You Won
Joo, Hyeong Seok
Park, Chae Won
Choi, Jae Woo
Kim, Dong Hwi
Kang, Han Na
Pyo, Kyoung‐Ho
Shin, Eun Joo
Shim, Hyo Sup
Soo, Ross A.
Yang, James Chih‐Hsin
Lee, Sung Sook
Chang, Hyun
Kim, Min Hwan
Hong, Min Hee
Kim, Hye Ryun
Cho, Byoung C.
- DOI
-
10.15252/emmm.201910581
- URN
-
urn:nbn:de:101:1-2022072007154831578737
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yun, Mi Ran
- Choi, Hun Mi
- Lee, You Won
- Joo, Hyeong Seok
- Park, Chae Won
- Choi, Jae Woo
- Kim, Dong Hwi
- Kang, Han Na
- Pyo, Kyoung‐Ho
- Shin, Eun Joo
- Shim, Hyo Sup
- Soo, Ross A.
- Yang, James Chih‐Hsin
- Lee, Sung Sook
- Chang, Hyun
- Kim, Min Hwan
- Hong, Min Hee
- Kim, Hye Ryun
- Cho, Byoung C.
Other Objects (12)
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
ALk
ALK
ALK
ALK
ALK
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
ALk
ALK
ALK
ALK
ALK
Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
ALk
ALK
ALK
ALK